<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Medical Journal of the Islamic Republic Of Iran</title>
<title_fa>مجله پزشکی جمهوری اسلامی ایران</title_fa>
<short_title>Med J Islam Repub Iran</short_title>
<subject>Medical Sciences</subject>
<web_url>http://mjiri.iums.ac.ir</web_url>
<journal_hbi_system_id>2</journal_hbi_system_id>
<journal_hbi_system_user>journal2</journal_hbi_system_user>
<journal_id_issn>1016-1430</journal_id_issn>
<journal_id_issn_online>2251-6840</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.18869/mjiri</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1384</year>
	<month>5</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2005</year>
	<month>8</month>
	<day>1</day>
</pubdate>
<volume>19</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>LONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY</title>
	<subject_fa>Oncology</subject_fa>
	<subject>Oncology</subject>
	<content_type_fa>Original Research: Basic Science in Medicine</content_type_fa>
	<content_type>Original Research: Basic Science in Medicine</content_type>
	<abstract_fa></abstract_fa>
	<abstract>Background: The activity and toxicity of etoposide in women with recurrent
ovarian cancer was evaluated in a case series of women with recurrent ovarian cancer
who had measurable disease,
Methods: All patients had plior platinum-based chemotherapy and developed
progressive disease, Etoposide was given as 50mg/day for 21 days every 4 weeks until
progression of disease or prohibitive toxicity, Between December 1999 and January
2004,32 patients were enrolled in this study.
Results: 30 patients received a total of 133 cycles of etoposide. Median age was
49 years (range, 19 to 75). The median number of etoposide cycles was 4 (range, 1 to
12). There were 5 partial responses (16.6%). The mean response duration was 4.8
months (range, 3.5 to 6). median progression-free interval CPFI) was 7 months (range,
3 to 13), and median survival time was 12.5 months (range. 1.3 to 36).
Conclusion: The major toxicity was leukopenia. One patient required red blood
cell transfusions, and the main non-hematologic toxicity was nausea and vomiting. There
were no treatment-related mortalities. Although etoposide appears to exhibit modest
activity in recurrent ovarian cancer after platinum-based therapy, response and survival
durations are short.
</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Oral etoposide, recurrent epithelial ovarian cancer, second-line chemotherapy</keyword>
	<start_page>159</start_page>
	<end_page>164</end_page>
	<web_url>http://mjiri.iums.ac.ir/browse.php?a_code=A-10-298-798&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>AZAM SADAT</first_name>
	<middle_name></middle_name>
	<last_name>MOOSAVI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>a3064@sina.tums.ac.ir </email>
	<code>20031947532846006640</code>
	<orcid>20031947532846006640</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>From the department of Gynecology /oncology, Vali Asr Hospital, Vali Asr reproductive Research center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>AFSANEH</first_name>
	<middle_name></middle_name>
	<last_name>TEHRANIAN</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006641</code>
	<orcid>20031947532846006641</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>From the department of Gynecology /oncology, Vali Asr Hospital, Vali Asr reproductive Research center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>NADEREH</first_name>
	<middle_name></middle_name>
	<last_name>BEHTASH</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006642</code>
	<orcid>20031947532846006642</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>From the department of Gynecology /oncology, Vali Asr Hospital, Vali Asr reproductive Research center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>MITRA</first_name>
	<middle_name></middle_name>
	<last_name>MODARES GILANI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006643</code>
	<orcid>20031947532846006643</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>From the department of Gynecology /oncology, Vali Asr Hospital, Vali Asr reproductive Research center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>FATEMEH</first_name>
	<middle_name></middle_name>
	<last_name>GHAEM-MAGHAMI</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>20031947532846006644</code>
	<orcid>20031947532846006644</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>From the department of Gynecology /oncology, Vali Asr Hospital, Vali Asr reproductive Research center, Tehran University of Medical Sciences, Tehran, Iran.</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
